Survodutide: Evidence, Mechanism, Dosing & Legal Status

Survodutide (development code BI 456906) is an investigational, once-weekly subcutaneous dual agonist of the GLP-1 and glucagon receptors — a glucagon-derived, albumin-binding acylated peptide co-discovered by Zealand Pharma and developed by Boehringer Ingelheim.78 Unlike most compounds in the peptide world, where consumer hype runs far ahead of human proof, survodutide's problem is the reverse: the evidence is strong, but the drug is not yet legally available. This monograph separates what is proven from what is pending.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Survodutide is an investigational drug not approved by any regulator as of June 2026; it is available only inside registered clinical trials and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is survodutide and how does it work?

Survodutide is a synthetic peptide built on the native glucagon backbone, engineered with amino-acid substitutions to confer GLP-1 receptor agonism while retaining glucagon-receptor (GCGR) activity, plus a C18 fatty-diacid acyl chain that drives reversible binding to serum albumin for half-life extension and once-weekly dosing.715 The molecular architecture leverages Zealand Pharma's peptide-engineering platform, with modifications conferring DPP-4 resistance and protection from endopeptidase cleavage.8

The mechanism is the story. Survodutide simultaneously activates the GLP-1 receptor and the glucagon receptor, and the two arms are complementary. The GLP-1 arm suppresses appetite and improves glycemic control (the incretin effect); the glucagon arm increases energy expenditure and acts directly on the liver to drive hepatic fat oxidation, reduce inflammation through improved mitochondrial function, and potentially attenuate stellate-cell-driven fibrosis.610 The combination — energy intake down via GLP-1, energy expenditure up via glucagon — is the mechanistic rationale for weight and hepatic benefit exceeding GLP-1 monoagonism, with the GLP-1 component deliberately weighted to offset glucagon's intrinsic hyperglycemic tendency.67 In vitro work reports an roughly 8-fold GLP-1R-over-GCGR potency bias, very high human serum albumin binding (>99%), and a plasma half-life of about 6 days.7 This GLP-1/glucagon design is distinct from tirzepatide's GLP-1/GIP mechanism. A dedicated Phase 1 study also characterized pharmacokinetics and tolerability in patients with cirrhosis.9

What is the evidence by indication?

Unlike most peptides in this library, survodutide's evidence base is human and randomized, not preclinical. Every indication below is supported by controlled trials, summarized in the table.

The obesity evidence is the deepest. The Phase 2 dose-finding RCT (NCT04667377) randomized 387 adults with BMI ≥27 and without type 2 diabetes to once-weekly survodutide (0.6, 2.4, 3.6, 4.8 mg) or placebo over 46 weeks; mean weight change at the highest dose was -14.9% versus -2.8% placebo, with about 18.7% in 4.8 mg completers and roughly 40% of that group losing at least 20% of starting weight.118 The completed Phase 3 SYNCHRONIZE-1 trial (725 adults) then met both co-primary endpoints, with weight reductions of -15.3% (3.6 mg) and -16.6% (6.0 mg) versus -3.2% placebo under the efficacy estimand; up to 85.1% achieved at least 5% loss and 28.5% of the 6.0 mg arm achieved at least 20% loss.34 Body-composition analyses showed weight loss came predominantly from fat mass with largely preserved lean mass, with visceral fat down up to ~34% and liver fat down up to ~63.1%.5 A prespecified post-hoc analysis also showed dose-dependent blood-pressure reduction (about -8.6 mmHg systolic at 4.8 mg).6

The MASH evidence is equally serious. The Phase 2 RCT published in the New England Journal of Medicine enrolled 293 patients with biopsy-confirmed MASH (fibrosis F1-F3) randomized to survodutide (2.4, 4.8, 6.0 mg) or placebo for 48 weeks. The primary endpoint — MASH improvement without fibrosis worsening — was reached by 47%, 62% and 43% of dose arms versus 14% placebo, with at least 30% liver-fat reduction in 63-67% versus 14%, and at least one-stage fibrosis improvement in 34-36% versus 22%.2 These data earned FDA Breakthrough Therapy status and triggered the large Phase 3 LIVERAGE and LIVERAGE-Cirrhosis programs; a Phase 3 SYNCHRONIZE-MASLD trial later reported liver-fat normalization in roughly 6 of 10 treated participants at 48 weeks.1316

What doses appear in the literature?

Reported strictly as information, not a protocol. Survodutide is given as a once-weekly subcutaneous injection.1 The obesity Phase 2 trial studied 0.6, 2.4, 3.6 and 4.8 mg; Phase 3 SYNCHRONIZE-1 used 3.6 and 6.0 mg; and the MASH Phase 2 trial used 2.4, 4.8 and 6.0 mg, with 4.8 mg and 6.0 mg serving as the high-efficacy maintenance doses.123 All trials used multi-week dose escalation — for example a 20-week escalation in the obesity Phase 2 and a 24-week rapid escalation in the MASH Phase 2 — to mitigate gastrointestinal effects, followed by a maintenance phase; investigators noted that slower escalation may reduce discontinuations.12 Because survodutide is unapproved, no public consumer or compounding reconstitution guidance exists, and it is not legally compoundable; any research-chemical preparation is unverified and outside any quality or sterility framework.

How safe is survodutide?

The most common adverse events are gastrointestinal. In the obesity Phase 2 trial, adverse events occurred in 91% of survodutide recipients versus 75% on placebo, predominantly nausea, vomiting and diarrhea in about 75% of recipients versus 42% on placebo; GI disorders were also the most frequent events in the MASH Phase 2 trial.12 Discontinuations occurred mainly during rapid dose-escalation and may be mitigated with slower titration, though discontinuation rates have been noted to exceed some comparators.10 A modest heart-rate increase (~3.2-3.5 bpm at week 76) was seen, consistent with the incretin/glucagon class, and asymptomatic pancreatic hyperenzymemia was slightly more common with survodutide — but no confirmed acute pancreatitis, pancreatic cancer or thyroid cancer was reported in SYNCHRONIZE-1.4 Class-based theoretical concerns inherited from GLP-1 agonists include medullary thyroid C-cell tumors (a rodent signal underlying the GLP-1-class MTC/MEN2 contraindication), pancreatitis, gallbladder events and hypoglycemia risk with insulin or sulfonylureas; pregnancy and breastfeeding are avoided per incretin/weight-loss norms.1 From a functional/integrative standpoint, the glucagon component may add hepatic-energy-expenditure and visceral-fat effects beyond appetite suppression, but the root-cause drivers of cardiometabolic disease — diet quality, insulin resistance, sleep, activity and environmental load — remain the substrate any pharmacotherapy acts upon.

What is the FDA and WADA status in 2026?

Survodutide is not approved (investigational). The FDA granted Breakthrough Therapy designation in September 2024 for adults with noncirrhotic MASH and moderate-to-advanced fibrosis, and it also holds Fast Track designation for NASH/MASH.111214 The EMA accepted it to the PRIME scheme for MASH in November 2023, and China's NMPA granted Breakthrough Therapy status in June 2024.15 As an unapproved new chemical entity it is not eligible for 503A or 503B pharmacy compounding; filing and possible approval are broadly anticipated around 2027 pending Phase 3 readouts.13

For athletes the picture is clear. Survodutide is not individually listed by WADA, but the 2026 Prohibited List bans non-approved substances under category S0 — prohibited at all times — and an investigational, unapproved agent like survodutide falls under S0; separately, the broader GLP-1 receptor agonist class sits on WADA's 2026 Monitoring Program.20 It is not a controlled substance under the DEA. Any material sold online as survodutide "for research use only" is unregulated, of unverified identity, purity and sterility, and outside any legal therapeutic channel.20

Bottom line. Survodutide pairs genuinely strong, randomized human evidence with a legal status that has not caught up: graded A in two indications, recognized by the FDA, EMA and NMPA, yet unapproved everywhere and banned in sport. The metabolic and hepatic efficacy is proven; superiority over the best approved agents is not. Key uncertainties — long-term cardiovascular outcomes (SYNCHRONIZE-CVOT pending), durability of fibrosis benefit (LIVERAGE pending) and T2D efficacy (SYNCHRONIZE-2 pending) — remain open. Anyone encountering survodutide outside a clinical trial is dealing with an unregulated research chemical, not a medicine. Regulatory facts here are current as of June 2026 and should be re-verified after upcoming readouts.